Strong growth, guidance held — CDMO ramp uncertain

Revenue ₹1,300.3 Cr, exactly +25.3% YoY with all segments contributing

EBITDA ₹209 Cr implied ~36% YoY growth; margin 16.1% vs ~11.8% prior year

PAT ₹105.8 Cr: 40.9% YoY, 22.4% QoQ — nearly exact match to claims

Volumes delayed due to customer pause on raw material pricing; full amount not served but EBITDA positive; specific contribution not disclosed

All three segments showing growth momentum in Q1; Niacinamide plant at 50% utilization targeting 70%; mechanism credible but dependent on CDMO volume ramp

25+ confirmed molecules (from 20 prior), 100+ total funnel with ₹3,500 Cr+ peak revenue. 5 new molecules added; pharma pipeline >3x post-US/Europe roadshow

Fine chemicals, CDMO, nutrition all showing volume growth + margin expansion. Fine chemicals coming off strong Q4 base; CDMO ramp underway

₹524 Cr revenue (+38% YoY), ₹57 Cr EBITDA (+240% YoY) driven by acetyl pricing and volume gains; Deepak confirmed strength continues in current quarter

Plant running smoothly. Supplies started March and continue. Did not serve full volumes Q1 due to customer-requested pause (raw material price escalation). Made good positive EBITDA on it; reflected in Q1 numbers. Full protection in place on expectations if volumes don't arrive.

Sticking with ₹750–800 Cr guidance. Sequential growth ~₹200 Cr in H1 (~₹400 Cr+). Chemical intermediates ~₹100 Cr annually. Bulk of growth from specialty & nutrition (70–80% mix). Volatility in acetyl segment is a risk for Q3–Q4.

5 new molecules are early-stage (pharma, personal care). Difficult to comment on peak potential now. Will update confirmed revenue potential as visibility improves with customers. Expected upside from them over time.

Carefully managed raw material inventory build. Finished goods prices came down from peak but not as much. Specialty CDMO & nutrition pricing held from Q1. War restart pushed prices up again. Impact minimal. Niacinamide plant already at 50%+ run rate targeting 70% by year-end.

B3 historically stays up 2–3 quarters when prices move. Q1 saw uplift with Q2 spillover. Possible decline by end-Q2 but high-value product mix (food/pharma/cosmetic grade) increasing, insulating us. Cost improvements underway. Q2 bookings already done; potential Q3 impact.

Constant discussions. Customer is also listed. Not given firm timeline but we need clarity within next month for Q3 planning. Hopeful for visibility by next month.

Portfolio approach. Different businesses fire different quarters. 3 years ago: ₹100 Cr EBITDA/qtr, now ₹209 Cr. Steady growth over time. Specialty fires some quarters, intermediates fire others (like this), nutrition fires others. All get EBITDA protection.

Significant investment in new MPP plant (Gajraula); on track for end-2026 commissioning per management

Large agro CDMO contract volumes delayed in Q1 due to customer pause (raw material pricing). Management stated full EBITDA protection but revenue upside at risk if ramp extends.

Chemical Intermediates surged ₹57 Cr EBITDA (+240% YoY) on acetyl pricing. Management explicitly flagged volatility and uncertainty for Q3–Q4; guidance not raised citing this risk.

5 new CDMO molecules added this quarter across pharma, personal care, semicon—all early-stage. Management did not update ₹1,500 Cr peak revenue guidance, indicating low visibility on peak potential of new additions.

B3 pricing historically volatile. Management noted prices up in Q1 with Q2 spillover but acknowledged possible decline by end-Q2 per historical patterns. Could impact nutrition segment margins in H2.

Power/fuel costs up due to LSHS/natural gas price increase from Gulf disruption. Logistics costs (domestic & international) also elevated. Passes through to customers but timing delays possible.